FAQ

Phosphodiesterase 3 Inhibitor [EPC]

Known as: Phosphodiesterase 3 Inhibitor, Phosphodiesterase III Inhibitor 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2014
01219962014

Related topics

Related topics

2 relations
Phosphodiesterase 3 InhibitorsPhosphodiesterase 3 Inhibitors [MoA]

Related mentions per year

Related mentions per year

1996-2016
1990200020102020
Phosphodiesterase 3 Inhibitor [EPC]
Phosphodiesterase 3 Inhibitors
Phosphodiesterase 3 Inhibitors [MoA]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Effects of cilostazol on the progression and regression of symptomatic intracranial artery stenosis: it reduces the risk of ischemic stroke
OBJECTIVE To assess the efficacy and safety of cilostazol on the progression and regression of symptomatic intracranial artery… (More)
  • figure 4
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
Efficacy of cilostazol in prevention of bradycardia during carotid artery stenting.
BACKGROUND Hypotension and bradycardia are known to occur frequently in carotid artery stenting (CAS), which may lead to… (More)
Is this relevant?
2014
2014
Effects of chronic treatment with cilostazol, a phosphodiesterase 3 inhibitor, on female rat bladder in a partial bladder outlet obstruction model.
OBJECTIVE To investigate whether bladder dysfunction after bladder outlet obstruction (BOO) could be altered by treatment with… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2010
Review
2010
Dual antiplatelet therapy in the secondary prevention of atherothrombosis: need for new therapeutic approaches.
MOTS CLÉS Association d’antiagrégants plaquettaires ; Maladie thrombotique More than 22 million Americans are estimated to take… (More)
  • table 1
Is this relevant?
2008
2008
Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation.
BACKGROUND Cilostazol, a phosphodiesterase 3 inhibitor, is an antiplatelet drug that is widely used for preventing cardiovascular… (More)
Is this relevant?
1999
1999
Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients.
The effect of topical administration of phosphodiesterase (PDE) 3 inhibitors on the airway is not clear. In order to examine the… (More)
Is this relevant?
1996
1996
Effects of selective phosphodiesterase 3 inhibition in the perfused liver of the rat after endotoxin treatment.
1. This study was designed to investigate the role of rat phosphodiesterase 3 (RPDE3) in regulation of liver metabolism in sepsis… (More)
Is this relevant?